<DOC>
	<DOCNO>NCT00279448</DOCNO>
	<brief_summary>To compare recurrence free survival two treatment group ( 5 year exemestane vs 2.5 3 year tamoxifen follow 2 2.5 year exemestane total duration 5 year ) This Pfizer sponsor trial part international collaboration investigator conduct 7 similar yet independent study 9 country . This study design part large TEAM trial data 7 study combine . A pre-specified analysis pool data conduct . Link TEAM Trial [ 971-ONC-0028-081/A5991026 ] Study Results : http : //clinicaltrials.gov/ct2/show/results/NCT00036270 ? term=971-ONC-0028-081 &amp; rank=1</brief_summary>
	<brief_title>Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>HR+ postmenopausal patient nonmetastatic breast cancer Any following : HR , nonmenopausal patient , metastatic breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>